Table 3.
Clinical and imaging features of Fibrothecoma and BLM.
| Characteristics | OF (n = 41) | BLM (n = 50) | P-value |
|---|---|---|---|
| Age | 52.85 ± 16.33 | 46.4 ± 9.27 | 0.02 |
| Tumor size | 8.35 ± 4.67 | 7.58 ± 3.85 | 0.62 |
| ADC (× 10–3 mm2/s) | 0.98 ± 0.21 | 0.94 ± 0.23 | 0.49 |
| r-T1 | 1.05 ± 0.18 | 0.82 ± 0.17 | < 0.01 |
| r-T2 | 2.42 ± 1.10 | 1.59 ± 1.04 | < 0.01 |
| Menopause status | 0.002 | ||
| Premenopausal | 12 (29.3%) | 31 (62%) | |
| Postmenopausal | 29 (70.7%) | 19 (38%) | |
| Tumor margin | 0.13 | ||
| Well-defined | 27 (65.9%) | 40 (80%) | |
| Ill-defined | 14 (34.1%) | 10 (20%) | |
| Component | < 0.01 | ||
| Solid | 23 (56.1%) | 48 (96%) | |
| Solid-cystic | 7 (17.1%) | 2 (4%) | |
| Cystic | 11 (26.8%) | 0 (0%) | |
| Shape | 0.87 | ||
| Smooth | 22 (53.7%) | 26 (52%) | |
| Lobulated | 19 (46.3%) | 24 (48%) | |
| Signal on DWI | 0.93 | ||
| Hyperintensity | 25 (29.3%) | 30 (60%) | |
| Isointensity | 16 (29.3%) | 20 (40%) | |
| Enhancement | < 0.01 | ||
| Mild | 19 (46.3%) | 5 (10%) | |
| Moderate | 16 (39.1%) | 6 (12%) | |
| Avid | 6 (14.6%) | 39 (78%) | |
| Associated myoma | 0.06 | ||
| Present | 9 (21.9%) | 20 (40%) | |
| Absent | 32 (78.1%) | 29 (58%) | |
| Stone paving sign | < 0.01 | ||
| Present | 11 (26.8%) | 33 (66%) | |
| Absent | 30 (73.2%) | 17 (34%) | |
| Ovary sign | < 0.01 | ||
| Present | 12 (29.3%) | 33 (66%) | |
| Absent | 29 (70.7%) | 17 (34%) | |
| Ascites | < 0.01 | ||
| Present | 35 (85.4%) | 21 (42%) | |
| Absent | 6 (14.6%) | 29 (58%) |
Values are given as n (%), mean ± SD (range).
OF ovary fibrothecoma, BLM broad ligament myoma, ADC apparent diffusion coefficient, r-T1 relative T1 value, r-T2 relative T2 value.